US20140187621A1 - Composition comprising coumestrol or a bean extract containing coumestrol - Google Patents

Composition comprising coumestrol or a bean extract containing coumestrol Download PDF

Info

Publication number
US20140187621A1
US20140187621A1 US14/200,070 US201414200070A US2014187621A1 US 20140187621 A1 US20140187621 A1 US 20140187621A1 US 201414200070 A US201414200070 A US 201414200070A US 2014187621 A1 US2014187621 A1 US 2014187621A1
Authority
US
United States
Prior art keywords
coumestrol
composition
bean extract
present disclosure
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/200,070
Inventor
Hee Y. Jeon
Hyun Jung Shin
Dae Bang Seo
Hyeon Ju YEO
Sang Jun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority to US14/200,070 priority Critical patent/US20140187621A1/en
Publication of US20140187621A1 publication Critical patent/US20140187621A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Definitions

  • the present disclosure relates to a composition comprising coumestrol or a bean extract comprising coumestrol.
  • Bean is of great nutritional value and contains various physiologically active and functional substances. Especially, since the phytoestrogens contained in bean are similar to the estrogen of mammals including human in structure, they have the effect of preventing chronic diseases such as hormonal disorders.
  • the phytoestrogens include in general isoflavone, coumestan and lignan.
  • the present disclosure is directed to providing a composition for inhibiting differentiation of adipocytes, enhancing immunity, detoxifying toxic substances, and preventing or improving degenerative neurological disorders, comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • the present disclosure provides a composition for inhibiting differentiation of adipocytes comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • the present disclosure provides a composition for enhancing immunity comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • the present disclosure provides a composition for detoxifying toxic substances comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • the present disclosure provides a composition for preventing or improving degenerative neurological disorders comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • composition according to an embodiment of the present disclosure which comprises coumestrol or a bean extract comprising coumestrol as an active ingredient, has the effect of inhibiting differentiation of adipocytes, enhancing immunity, detoxifying toxic substances, and preventing or improving degenerative neurological disorders.
  • the composition is useful in the field of food or medicine.
  • FIG. 1 shows inhibition of adipocyte differentiation by coumestrol.
  • FIG. 2 shows decreased expression of adipocyte marker genes by coumestrol.
  • extract means a substance extracted from a natural substance, regardless of extraction method or ingredients.
  • the term is used in a broad sense including, for example, ingredients soluble in water or an organic solvent extracted from a natural substance using the solvent, or specific ingredients of a natural substance such as oil extracted therefrom.
  • the present disclosure provides a composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • Coumestrol (CMS; 3,9-dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one) has a structure of Chemical Formula 1:
  • Coumestrol is one of phytoestrogens and is usually found in the seed, root or leaf of plants in the family Leguminosae or Compositae. It can be classified as a coumestan-like isoflavonoid and is known to have an estrogenic effect.
  • the composition comprises coumestrol, a natural substance comprising coumestrol or an extract thereof.
  • the natural substance comprising coumestrol may be one or more bean selected from soybean, pea, mung bean and sprouted beans sprouted therefrom, red clover (alfalfa), Brussels sprout, or the like.
  • the natural substance comprising coumestrol may be bean.
  • the bean may be any plant comprising coumestrol in the family Leguminosae, without particular limitation.
  • the ban that can be used in the present disclosure may be one for bean paste, bean curd, namul, rice cooking or green bean.
  • the bean varieties for bean paste or bean curd include daepung, hojang, jangwon, daehwang, sodam, songhak, daewon, jinpum, danbaek, duyu, shinpaldal, taegwang, manli, jangsu, muhan, baegun, saeal, hwangkeum and jangyeop.
  • the bean varieties for namul include shinhwa, sowon, anpyeong, seonam, dachae, sorok, soho, somyeong, dawon, pungsan-namul, iksan-namul, sobaek-namul, gwangan, danyeop and eunha.
  • the bean varieties for rice cooking include cheongja, heukcheong, galmi, seonheuk, geomjeong-kong and ilpumgeomjeong-kong.
  • the bean varieties for green bean include daol, shinrok, saeul, geomjeongeul, seokryang-putkong, hwaeom-putkong and keuneul.
  • the bean may be one that can be sprouted and is resistant to damage from disease and harmful insects.
  • Such bean varieties include, for example, shinhwa, sowon, anpyeong, seonam, dachae, sorok, soho, somyeong, dawon, pungsan-namul, iksan-namul, sobaek-namul, gwangan, danyeop and eunha.
  • the natural substance or the extract thereof may comprise a large quantity of coumestrol. Specifically, it may comprise 0.01-50 wt %, more specifically 0.1-30 wt %, of coumestrol based on the total weight of the natural substance or the extract thereof.
  • the extract of the natural substance comprising coumestrol may be obtained by extracting the natural substance comprising coumestrol with water or ethanol at normal or elevated temperature, completely concentrating the resulting extract and dispersing again in water, and fractionating with one or more solvent of equal volume selected from hexane, dichloromethane, chloroform, ethyl acetate, butanol, ethanol, methanol and water.
  • the extraction method is not limited thereto and any extraction method may be employed.
  • the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for inhibiting differentiation of adipocytes.
  • Coumestrol inhibits differentiation of adipocytes and decreases mRNA expression of molecular markers of adipocyte differentiation and fatty acid synthesis.
  • the composition comprising coumestrol may inhibit differentiation of adipocytes and prevent or improve obesity and various diseases induced by obesity. Examples of such diseases include type 2 diabetes, fatty liver or cardiovascular diseases, but are not limited thereto.
  • the cardiovascular disease includes one or more of hyperlipidemia, hypertension, angina, myocardial infarction and arteriosclerosis.
  • the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for enhancing immunity.
  • Coumestrol enhances immunity and activates immune cells by proliferating the immune cells.
  • the composition comprising coumestrol may enhance immunity and protect the body from microbes, ‘bacteria, viruses, etc.
  • the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for detoxifying toxic substances.
  • the composition may detoxify toxic substances ingested into the body. Particularly, it has an excellent ability of detoxifying nicotine. Nicotine is an addiction-inducing substance contained in cigarettes and may cause negative cardiovascular effects by stimulating the sympathetic nervous system.
  • Coumestrol increases viability of vascular endothelial cells by protecting the vascular endothelial cells from nicotine or other toxic substances.
  • the composition comprising coumestrol may detoxify nicotine or other toxic substances ingested into the body and prevent or improve vascular diseases caused by the toxic substances. Examples of the vascular diseases may include blood circulation disorder, hypertension or arteriosclerosis, but are not limited thereto.
  • the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for preventing or improving degenerative neurological disorders.
  • the degenerative neurological disorders refer to the diseases occurring as a result of degenerative damage and deteriorated function of nerves or nerve cells. Examples of the degenerative neurological disorders may include glaucoma, glaucoma, myasthenia gravis, diabetic neuropathy, cerebrovascular accident, spinal cord injury, Lou Gehrig's disease (amyotrophic lateral sclerosis; ALS), Parkinson's disease, Alzheimer's disease or idiopathic dementia, but are not limited thereto.
  • Coumestrol increases viability of nerve cells by protecting them from neurotoxins and scavenges reactive oxygen species produced by neurotoxins. Accordingly, the composition comprising coumestrol may prevent or improve degenerative neurological disorders by inhibiting the action of neurotoxins.
  • composition according to an embodiment of the present disclosure may comprise 0.001-30 wt %, specifically 0.01-10 wt %, more specifically 0.1-5 wt %, of coumestrol or a bean extract comprising coumestrol based on the total weight of the composition.
  • coumestrol or the bean extract comprising coumestrol is included in the above-described range, the intended effect of the present disclosure can be adequately achieved while both stability and safety are satisfied and favorable cost-effectiveness may be achieved.
  • the present disclosure provides a food composition comprising coumestrol or a bean extract comprising coumestrol.
  • the food composition may be a health food, functional food or food additive composition.
  • the food composition may comprise other ingredients providing synergic effect without negatively affecting the desired effect.
  • additives such as fragrance, pigment, sterilizer, antioxidant, antiseptic, moisturizer, thickener, mineral, emulsifier, synthetic polymer, etc.
  • auxiliary ingredients such as water-soluble vitamin, oil-soluble vitamin, polymer peptide, polymer polysaccharide, and seaweed extract, etc. may be further included. These ingredients may be selected by those skilled in the art without difficulty considering the particular formulation or purpose of use. The addition amount may be determined within the range not negatively affecting the purpose and effect of the present disclosure.
  • composition according to the present disclosure may be prepared into various formulations including solution, emulsion, viscous mixture, tablet, powder, etc.
  • the dose of the active ingredient is within the level of those skilled in the art.
  • the dose may be 0.1-5000 mg/kg/day, more specifically 50-500 mg/kg/day, but is not limited thereto, and may be varied with various factors including the age, physical condition, complication, etc. of a subject to be treated.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising coumestrol or a bean extract comprising coumestrol.
  • the pharmaceutical composition may further comprise a pharmaceutical adjuvant such as antiseptic, stabilizer, hydrating agent, emulsifying accelerator, salt and/or buffer for controlling osmotic pressure, etc. or other therapeutically useful substance, and may be prepared into various formulations for oral or parenteral administration.
  • the formulation for oral administration may include, for example, tablet, pill, hard or soft capsule, liquid, suspension, emulsion, syrup, powder, dust, granule, pellet, or the like.
  • These formulations may comprise, in addition to the active ingredient, a surfactant, a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine) or a lubricant (e.g., silica, talc, stearic acid and magnesium or calcium salt thereof or polyethylene glycol).
  • a surfactant e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine
  • a lubricant e.g., silica, talc, stearic acid and magnesium or calcium salt thereof or polyethylene glycol.
  • the tablet may comprise a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose and polyvinylpyrrolidone, and may occasionally comprise a pharmaceutical additive such as a disintegrant, e.g. starch, agar, alginic acid or a sodium salt thereof, an absorbent, a colorant, a flavor, a sweetener, or the like.
  • a disintegrant e.g. starch, agar, alginic acid or a sodium salt thereof, an absorbent, a colorant, a flavor, a sweetener, or the like.
  • the tablet may be prepared according to the commonly employed mixing, granulation or coating method.
  • the formulation for parenteral administration may include, for example, injection, drop, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, etc., but is not limited thereto.
  • a pharmaceutically acceptable amount, i.e. administration dose, of the dose of the active ingredient will vary depending on the age, sex and body weight of the subject to be treated, severity of particular disease or pathological condition to be treated, administration route and discretion of the prescriber. Those skilled in the art may determine the administration dose considering the known bioavailability of coumestrol upon oral administration (about 11.7%) as well as the above-described factors. For example, a general administration dose may be 0.01-1000 mg/kg/day, specifically 1-40 mg/kg/day. However, the described administration dose does not limit the scope of the present disclosure by any means.
  • test examples are provided for illustrative purposes only and are not intended to limit the scope of the present disclosure.
  • CMS coumestrol
  • 3T3-L1 mouse preadipocytes CL-173, ATCC
  • BBR berberine
  • adipocyte differentiation was identified by staining triglycerides in the cells with Oil Red O (Sigma). The result is shown in FIG. 1 .
  • the group treated with coumestrol showed less stained area than those treated with the positive control rosiglitazone or the negative control berberine. This means that adipocyte differentiation is remarkably decreased by coumestrol and the effect is superior to that of berberine.
  • adipocyte-specific genes in the in the adipocytes was investigated by Q-PCR. The expression level of each group relative to the untreated group was evaluated and is shown in FIG. 2 .
  • the genes tested were aP2 (fatty acid binding protein 4, adipocyte specific type), Acrp30 (adiponectin), PPAR (peroxisome proliferator-activated receptor), SREBP1c (sterol regulatory element binding protein 1c) and FAS (fatty acid synthase), which are used as molecular markers of adipocyte differentiation and fatty acid synthesis.
  • coumestrol resulted in remarkably decreased mRNA expression of the molecular markers of adipocyte differentiation and fatty acid synthesis, and the effect was better than that of berberine.
  • coumestrol inhibits adipocyte differentiation and fatty acid synthesis. Accordingly, the composition comprising coumestrol may prevent or improve obesity and may prevent or improve type 2 diabetes, fatty liver, cardiovascular disease, etc. caused by obesity.
  • Spleen was aseptically removed from an ICR mouse sacrificed by cervical dislocation.
  • the spleen was washed with an RPMI 1640 solution and lightly smashed with a sterilized glass rod to isolate the mouse spleen cells.
  • a suspension of the isolated cells was passed through a 200-mesh stainless steel sieve (Sigma Chemical Co., St. Louis, Mo., USA) and centrifuged for 10 minutes at 4 ° C. and 3,000 rpm in a 50-mL centrifuge tube.
  • the resulting cell pellets were suspended in a lysing buffer (Tris-buffered ammonium chloride; 0.87% NH 4 Cl, pH 7.2) for 5 minutes to remove red blood cells.
  • Tris-buffered ammonium chloride Tris-buffered ammonium chloride; 0.87% NH 4 Cl, pH 7.2
  • the cells were washed twice with RPMI by centrifugal washing, diluted to 5.0 ⁇ 10 6 cells/mL in 10%-FBS RPMI 1640, and seeded on a 96-well plate, with 90 ⁇ L per each well, for measurement of cell proliferating activity.
  • the cells were cultured for 44 hours and the proliferating activity of the spleen cells was measured (CCK-8, Dojindo Laboratories, Japan). 10 ⁇ L of 10 ⁇ g/mL LPS was used as positive control.
  • the immune cell proliferating activity (%) of each group relative to the untreated group was measured and is shown in Table 1.
  • coumestrol promotes proliferation of immune cells, and the effect is better than that of the positive control at higher concentration. Accordingly, the composition comprising coumestrol may provide a superior effect of enhancing immunity by activating immune cells.
  • HUVECs Human umbilical vein endothelial cells (HUVECs, CRL-2873, ATCC) were used to evaluate the coumestrol's effect against nicotine which is a major toxic substance included in cigarettes.
  • HUVECs were cultured under the condition of 37° C. and 5% CO 2 using the microvascular endothelial cell growth medium-2 (EGM-2).
  • the cells were seeded onto a 96-well plate, with 2 ⁇ 10 4 cells per well, and cultured for about 24 hours in a medium containing 10% FBS until ⁇ 80% confluency. After treating with nicotine to a final concentration of 25 mM, the cells were cultured for 24 hours with 0.1, 1 or 10 ⁇ M coumestrol, except for the negative control group. The viability (%) of the vascular endothelial cells was evaluated relative to the untreated group and is given in Table 2.
  • coumestrol increases the viability of vascular endothelial cells by detoxifying nicotine. Accordingly, the composition comprising coumestrol may detoxify toxic substances ingested into the body and prevent or improve vascular diseases caused thereby.
  • SH-SY5Y cells (CRL-2266, ATCC) were used to evaluate the coumestrol's effect of protecting nerve cells from neurotoxins.
  • the cells were cultured in a medium comprising 90% DMEM, 10% fetal calf serum, 100 IU/mL penicillin and 100 ⁇ g/mL streptomycin under the condition of 37° C. and 5% CO 2 .
  • the cells grew confluent, they were harvested with trypsin, diluted on a 96-well plate to 1 ⁇ 10 4 cells per well, and then grafted onto a culture dish. 24 hours later, after treating the cultured cells with 0.01, 0.1 or 1 ⁇ M coumestrol, the cells were treated with 50 ⁇ M 6-OHDA 2 hours later to induce cytotoxicity.
  • a negative control group was treated only with 50 ⁇ M 6-OHDA.
  • the viability (%) of the nerve cells was measured by MIT assay 24 hours later and the result is shown in Table 3.
  • mitochondrial potential of the cells was measured using the JC-1 fluorescent reagent (Beyotime, China). The effect of inhibiting decline of mitochondrial potential (%) is shown in Table 4.
  • coumestrol increases the viability of nerve cells in the presence of neurotoxins and has an excellent effect of inhibiting decline of mitochondrial potential.
  • the same cells used in Test Example 4-1 were cultured under the same condition.
  • the cultured cells were treated with 0.01, 0.1 or 1 ⁇ M coumestrol and then treated with 50 ⁇ M 6-OHDA 2 hours later to induce increase of reactive oxygen species (ROS) in the cells.
  • ROS reactive oxygen species
  • the fluorescence intensity of DCF was measured with the Wallac VICTOR2 fluorometer (Wallac, Turku, Finland) at excitation wavelength of 485 nm and emission wavelength of 530 nm.
  • ROS scavenging effect (%) relative to the negative control group was calculated from the measured fluorescence intensity. The result is given in Table 5.
  • coumestrol has an excellent effect of scavenging ROS produced by neurotoxins.
  • composition comprising coumestrol may prevent or improve degenerative neurological disorders by inhibiting the action of neurotoxins.
  • Coumestrol 80 mg
  • vitamin E 9 mg
  • vitamin C 9 mg
  • palm oil 2 mg
  • hydrogenated vegetable oil 8 mg
  • yellow beeswax 4 mg
  • lecithin 9 mg
  • 400 mg of the solution is filled per capsule.
  • a soft capsule sheet is prepared using gelatin 66 (wt %), glycerin (24 wt %) and sorbitol (10 wt %), which is filled with the filling solution to prepare a soft capsule containing 400 mg of the composition according to the present disclosure.
  • Coumestrol 80 mg
  • vitamin E 9 mg
  • vitamin C 9 mg
  • galactooligosaccharide 200 mg
  • lactose 60 mg
  • maltose 140 mg
  • Coumestrol 80 mg
  • vitamin E 9 mg
  • vitamin C 9 mg
  • citric acid 0.6 g
  • oligosaccharide syrup 25 g
  • purified water 300 mL
  • 200 mL of the resulting mixture is filled in a bottle.
  • a drink is prepared by sterilizing at 130° C. for 4-5 seconds.
  • Coumestrol 80 mg
  • vitamin E 9 mg
  • vitamin C 9 mg
  • anhydrous crystalline glucose 250 mg
  • starch 550 mg
  • An injection is prepared using the above ingredients per ampule (2 mL) according to a commonly employed method.

Abstract

The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved.

Description

    TECHNICAL FIELD
  • The present disclosure relates to a composition comprising coumestrol or a bean extract comprising coumestrol.
  • BACKGROUND ART
  • Bean is of great nutritional value and contains various physiologically active and functional substances. Especially, since the phytoestrogens contained in bean are similar to the estrogen of mammals including human in structure, they have the effect of preventing chronic diseases such as hormonal disorders. The phytoestrogens include in general isoflavone, coumestan and lignan.
  • DISCLOSURE Technical Problem
  • The present disclosure is directed to providing a composition for inhibiting differentiation of adipocytes, enhancing immunity, detoxifying toxic substances, and preventing or improving degenerative neurological disorders, comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • Technical Solution
  • In an aspect, the present disclosure provides a composition for inhibiting differentiation of adipocytes comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • In another aspect, the present disclosure provides a composition for enhancing immunity comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • In another aspect, the present disclosure provides a composition for detoxifying toxic substances comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • In another aspect, the present disclosure provides a composition for preventing or improving degenerative neurological disorders comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • Advantageous Effects
  • The composition according to an embodiment of the present disclosure, which comprises coumestrol or a bean extract comprising coumestrol as an active ingredient, has the effect of inhibiting differentiation of adipocytes, enhancing immunity, detoxifying toxic substances, and preventing or improving degenerative neurological disorders. The composition is useful in the field of food or medicine.
  • DESCRIPTION OF DRAWINGS
  • FIG. 1 shows inhibition of adipocyte differentiation by coumestrol.
  • FIG. 2 shows decreased expression of adipocyte marker genes by coumestrol.
  • MODE FOR INVENTION
  • As used herein, “extract” means a substance extracted from a natural substance, regardless of extraction method or ingredients. The term is used in a broad sense including, for example, ingredients soluble in water or an organic solvent extracted from a natural substance using the solvent, or specific ingredients of a natural substance such as oil extracted therefrom.
  • Hereinafter, the present disclosure is described in further detail.
  • In an aspect, the present disclosure provides a composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient.
  • Coumestrol (CMS; 3,9-dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one) has a structure of Chemical Formula 1:
  • Figure US20140187621A1-20140703-C00001
  • Coumestrol is one of phytoestrogens and is usually found in the seed, root or leaf of plants in the family Leguminosae or Compositae. It can be classified as a coumestan-like isoflavonoid and is known to have an estrogenic effect.
  • In an exemplary embodiment of the present disclosure, the composition comprises coumestrol, a natural substance comprising coumestrol or an extract thereof. In another exemplary embodiment of the present disclosure, the natural substance comprising coumestrol may be one or more bean selected from soybean, pea, mung bean and sprouted beans sprouted therefrom, red clover (alfalfa), Brussels sprout, or the like. In another exemplary embodiment of the present disclosure, the natural substance comprising coumestrol may be bean.
  • In an exemplary embodiment of the present disclosure, the bean may be any plant comprising coumestrol in the family Leguminosae, without particular limitation. For example, the ban that can be used in the present disclosure may be one for bean paste, bean curd, namul, rice cooking or green bean. The bean varieties for bean paste or bean curd include daepung, hojang, jangwon, daehwang, sodam, songhak, daewon, jinpum, danbaek, duyu, shinpaldal, taegwang, manli, jangsu, muhan, baegun, saeal, hwangkeum and jangyeop. The bean varieties for namul include shinhwa, sowon, anpyeong, seonam, dachae, sorok, soho, somyeong, dawon, pungsan-namul, iksan-namul, sobaek-namul, gwangan, danyeop and eunha. The bean varieties for rice cooking include cheongja, heukcheong, galmi, seonheuk, geomjeong-kong and ilpumgeomjeong-kong. And, the bean varieties for green bean include daol, shinrok, saeul, geomjeongeul, seokryang-putkong, hwaeom-putkong and keuneul. In another exemplary embodiment of the present disclosure, the bean may be one that can be sprouted and is resistant to damage from disease and harmful insects. Such bean varieties include, for example, shinhwa, sowon, anpyeong, seonam, dachae, sorok, soho, somyeong, dawon, pungsan-namul, iksan-namul, sobaek-namul, gwangan, danyeop and eunha.
  • In an exemplary embodiment of the present disclosure, the natural substance or the extract thereof may comprise a large quantity of coumestrol. Specifically, it may comprise 0.01-50 wt %, more specifically 0.1-30 wt %, of coumestrol based on the total weight of the natural substance or the extract thereof.
  • In an exemplary embodiment of the present disclosure, the extract of the natural substance comprising coumestrol may be obtained by extracting the natural substance comprising coumestrol with water or ethanol at normal or elevated temperature, completely concentrating the resulting extract and dispersing again in water, and fractionating with one or more solvent of equal volume selected from hexane, dichloromethane, chloroform, ethyl acetate, butanol, ethanol, methanol and water. However, the extraction method is not limited thereto and any extraction method may be employed.
  • In an exemplary embodiment of the present disclosure, the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for inhibiting differentiation of adipocytes. Coumestrol inhibits differentiation of adipocytes and decreases mRNA expression of molecular markers of adipocyte differentiation and fatty acid synthesis. Accordingly, the composition comprising coumestrol may inhibit differentiation of adipocytes and prevent or improve obesity and various diseases induced by obesity. Examples of such diseases include type 2 diabetes, fatty liver or cardiovascular diseases, but are not limited thereto. The cardiovascular disease includes one or more of hyperlipidemia, hypertension, angina, myocardial infarction and arteriosclerosis.
  • In an exemplary embodiment of the present disclosure, the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for enhancing immunity. Coumestrol enhances immunity and activates immune cells by proliferating the immune cells. Accordingly, the composition comprising coumestrol may enhance immunity and protect the body from microbes, ‘bacteria, viruses, etc.
  • In an exemplary embodiment of the present disclosure, the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for detoxifying toxic substances. The composition may detoxify toxic substances ingested into the body. Particularly, it has an excellent ability of detoxifying nicotine. Nicotine is an addiction-inducing substance contained in cigarettes and may cause negative cardiovascular effects by stimulating the sympathetic nervous system. Coumestrol increases viability of vascular endothelial cells by protecting the vascular endothelial cells from nicotine or other toxic substances. Accordingly, the composition comprising coumestrol may detoxify nicotine or other toxic substances ingested into the body and prevent or improve vascular diseases caused by the toxic substances. Examples of the vascular diseases may include blood circulation disorder, hypertension or arteriosclerosis, but are not limited thereto.
  • In an exemplary embodiment of the present disclosure, the composition comprising coumestrol or a bean extract comprising coumestrol as an active ingredient may be a composition for preventing or improving degenerative neurological disorders. The degenerative neurological disorders refer to the diseases occurring as a result of degenerative damage and deteriorated function of nerves or nerve cells. Examples of the degenerative neurological disorders may include glaucoma, glaucoma, myasthenia gravis, diabetic neuropathy, cerebrovascular accident, spinal cord injury, Lou Gehrig's disease (amyotrophic lateral sclerosis; ALS), Parkinson's disease, Alzheimer's disease or idiopathic dementia, but are not limited thereto. Coumestrol increases viability of nerve cells by protecting them from neurotoxins and scavenges reactive oxygen species produced by neurotoxins. Accordingly, the composition comprising coumestrol may prevent or improve degenerative neurological disorders by inhibiting the action of neurotoxins.
  • The composition according to an embodiment of the present disclosure may comprise 0.001-30 wt %, specifically 0.01-10 wt %, more specifically 0.1-5 wt %, of coumestrol or a bean extract comprising coumestrol based on the total weight of the composition. When the coumestrol or the bean extract comprising coumestrol is included in the above-described range, the intended effect of the present disclosure can be adequately achieved while both stability and safety are satisfied and favorable cost-effectiveness may be achieved.
  • In another aspect, the present disclosure provides a food composition comprising coumestrol or a bean extract comprising coumestrol. The food composition may be a health food, functional food or food additive composition.
  • The food composition may comprise other ingredients providing synergic effect without negatively affecting the desired effect. For example, additives such as fragrance, pigment, sterilizer, antioxidant, antiseptic, moisturizer, thickener, mineral, emulsifier, synthetic polymer, etc. may be further included. In addition, auxiliary ingredients such as water-soluble vitamin, oil-soluble vitamin, polymer peptide, polymer polysaccharide, and seaweed extract, etc. may be further included. These ingredients may be selected by those skilled in the art without difficulty considering the particular formulation or purpose of use. The addition amount may be determined within the range not negatively affecting the purpose and effect of the present disclosure.
  • The composition according to the present disclosure may be prepared into various formulations including solution, emulsion, viscous mixture, tablet, powder, etc.
  • Determination of the dose of the active ingredient is within the level of those skilled in the art. For example, the dose may be 0.1-5000 mg/kg/day, more specifically 50-500 mg/kg/day, but is not limited thereto, and may be varied with various factors including the age, physical condition, complication, etc. of a subject to be treated.
  • In another aspect, the present disclosure provides a pharmaceutical composition comprising coumestrol or a bean extract comprising coumestrol. The pharmaceutical composition may further comprise a pharmaceutical adjuvant such as antiseptic, stabilizer, hydrating agent, emulsifying accelerator, salt and/or buffer for controlling osmotic pressure, etc. or other therapeutically useful substance, and may be prepared into various formulations for oral or parenteral administration.
  • The formulation for oral administration may include, for example, tablet, pill, hard or soft capsule, liquid, suspension, emulsion, syrup, powder, dust, granule, pellet, or the like. These formulations may comprise, in addition to the active ingredient, a surfactant, a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine) or a lubricant (e.g., silica, talc, stearic acid and magnesium or calcium salt thereof or polyethylene glycol). The tablet may comprise a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose and polyvinylpyrrolidone, and may occasionally comprise a pharmaceutical additive such as a disintegrant, e.g. starch, agar, alginic acid or a sodium salt thereof, an absorbent, a colorant, a flavor, a sweetener, or the like. The tablet may be prepared according to the commonly employed mixing, granulation or coating method.
  • The formulation for parenteral administration may include, for example, injection, drop, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, etc., but is not limited thereto.
  • A pharmaceutically acceptable amount, i.e. administration dose, of the dose of the active ingredient will vary depending on the age, sex and body weight of the subject to be treated, severity of particular disease or pathological condition to be treated, administration route and discretion of the prescriber. Those skilled in the art may determine the administration dose considering the known bioavailability of coumestrol upon oral administration (about 11.7%) as well as the above-described factors. For example, a general administration dose may be 0.01-1000 mg/kg/day, specifically 1-40 mg/kg/day. However, the described administration dose does not limit the scope of the present disclosure by any means.
  • The features and effects of the present disclosure will be described in detail through test examples. However, the following test examples are provided for illustrative purposes only and are not intended to limit the scope of the present disclosure.
  • TEST EXAMPLE 1 Evaluation of Effect of Inhibiting Adipocyte Differentiation
  • In order to evaluate the coumestrol's effect of inhibiting adipocyte differentiation, 10 M coumestrol (CMS) was administered continuously while 3T3-L1 mouse preadipocytes (CL-173, ATCC) were differentiated into adipocytes. 1 M Rosiglitazone (Rosi), which is known to promote adipocyte differentiation, was used as positive control and 10 M berberine (BBR), which is known to inhibit adipocyte differentiation, was used as negative control. On the day when adipocyte differentiation was started and on days 2, 4 and 6, the test substance was administered and the medium was changed. The adipocyte differentiation was carried out for about 7 days when the adipocyte differentiation was completed in the positive control group.
  • Then, differentiation of adipocytes was identified by staining triglycerides in the cells with Oil Red O (Sigma). The result is shown in FIG. 1. As seen from FIG. 1, the group treated with coumestrol showed less stained area than those treated with the positive control rosiglitazone or the negative control berberine. This means that adipocyte differentiation is remarkably decreased by coumestrol and the effect is superior to that of berberine.
  • Also, expression of adipocyte-specific genes in the in the adipocytes was investigated by Q-PCR. The expression level of each group relative to the untreated group was evaluated and is shown in FIG. 2. The genes tested were aP2 (fatty acid binding protein 4, adipocyte specific type), Acrp30 (adiponectin), PPAR (peroxisome proliferator-activated receptor), SREBP1c (sterol regulatory element binding protein 1c) and FAS (fatty acid synthase), which are used as molecular markers of adipocyte differentiation and fatty acid synthesis. As seen from FIG. 2, coumestrol resulted in remarkably decreased mRNA expression of the molecular markers of adipocyte differentiation and fatty acid synthesis, and the effect was better than that of berberine.
  • Thus, coumestrol inhibits adipocyte differentiation and fatty acid synthesis. Accordingly, the composition comprising coumestrol may prevent or improve obesity and may prevent or improve type 2 diabetes, fatty liver, cardiovascular disease, etc. caused by obesity.
  • TEST EXAMPLE 2 Evaluation of Immune Cell Activating Effect
  • Spleen was aseptically removed from an ICR mouse sacrificed by cervical dislocation. The spleen was washed with an RPMI 1640 solution and lightly smashed with a sterilized glass rod to isolate the mouse spleen cells. A suspension of the isolated cells was passed through a 200-mesh stainless steel sieve (Sigma Chemical Co., St. Louis, Mo., USA) and centrifuged for 10 minutes at 4 ° C. and 3,000 rpm in a 50-mL centrifuge tube. The resulting cell pellets were suspended in a lysing buffer (Tris-buffered ammonium chloride; 0.87% NH4Cl, pH 7.2) for 5 minutes to remove red blood cells. The cells were washed twice with RPMI by centrifugal washing, diluted to 5.0×106cells/mL in 10%-FBS RPMI 1640, and seeded on a 96-well plate, with 90 μL per each well, for measurement of cell proliferating activity. After preparing a stock solution such that the final concentration of coumestrol was 0.1 or 1 μM and adding 10 μL to each well, the cells were cultured for 44 hours and the proliferating activity of the spleen cells was measured (CCK-8, Dojindo Laboratories, Japan). 10 μL of 10 μg/mL LPS was used as positive control. The immune cell proliferating activity (%) of each group relative to the untreated group was measured and is shown in Table 1.
  • TABLE 1
    Immune cell proliferating
    activity (%)
    Untreated 100
    LPS ,10 μg/mL (positive control) 275
    Coumestrol, 0.1 μM 278
    Coumestrol, 1 μM 283
  • As seen from Table 1, coumestrol promotes proliferation of immune cells, and the effect is better than that of the positive control at higher concentration. Accordingly, the composition comprising coumestrol may provide a superior effect of enhancing immunity by activating immune cells.
  • TEST EXAMPLE 3 Evaluation of Nicotine Detoxifying Effect
  • Human umbilical vein endothelial cells (HUVECs, CRL-2873, ATCC) were used to evaluate the coumestrol's effect against nicotine which is a major toxic substance included in cigarettes. HUVECs were cultured under the condition of 37° C. and 5% CO2 using the microvascular endothelial cell growth medium-2 (EGM-2).
  • The cells were seeded onto a 96-well plate, with 2×104 cells per well, and cultured for about 24 hours in a medium containing 10% FBS until ˜80% confluency. After treating with nicotine to a final concentration of 25 mM, the cells were cultured for 24 hours with 0.1, 1 or 10 μM coumestrol, except for the negative control group. The viability (%) of the vascular endothelial cells was evaluated relative to the untreated group and is given in Table 2.
  • TABLE 2
    Viability of vascular
    endothelial cells (%)
    Untreated 100
    Negative control 55.1
    Coumestrol, 0.1 μM 67.2
    Coumestrol, 1 μM 72.2
    Coumestrol, 10 μM 88.9
  • As seen from Table 2, coumestrol increases the viability of vascular endothelial cells by detoxifying nicotine. Accordingly, the composition comprising coumestrol may detoxify toxic substances ingested into the body and prevent or improve vascular diseases caused thereby.
  • TEST EXAMPLE 4 Evaluation of Effect of Inhibiting Neurotoxins
  • 1. Evaluation of Effect of Protecting Nerve Cells from Neurotoxins
  • SH-SY5Y cells (CRL-2266, ATCC) were used to evaluate the coumestrol's effect of protecting nerve cells from neurotoxins. The cells were cultured in a medium comprising 90% DMEM, 10% fetal calf serum, 100 IU/mL penicillin and 100 μg/mL streptomycin under the condition of 37° C. and 5% CO2. When the cells grew confluent, they were harvested with trypsin, diluted on a 96-well plate to 1×104 cells per well, and then grafted onto a culture dish. 24 hours later, after treating the cultured cells with 0.01, 0.1 or 1 μM coumestrol, the cells were treated with 50 μM 6-OHDA 2 hours later to induce cytotoxicity. A negative control group was treated only with 50 μM 6-OHDA. The viability (%) of the nerve cells was measured by MIT assay 24 hours later and the result is shown in Table 3. Also, mitochondrial potential of the cells was measured using the JC-1 fluorescent reagent (Beyotime, China). The effect of inhibiting decline of mitochondrial potential (%) is shown in Table 4.
  • TABLE 3
    Viability of nerve
    cells (%)
    Untreated 100
    Negative control (50 μM 6-OHDA) 78.6
    Coumestrol, 0.01 μM 94.4
    Coumestrol, 0.1 μM 96.5
    Coumestrol, 1 μM 98.2
  • TABLE 4
    Effect of inhibiting decline of
    mitochondrial potential (%)
    Negative control 0
    (50 μM 6-OHDA)
    Coumestrol, 0.01 μM 13.2
    Coumestrol, 0.1 μM 29.1
    Coumestrol, 1 μM 43.0
  • As seen from Tables 3 and 4, coumestrol increases the viability of nerve cells in the presence of neurotoxins and has an excellent effect of inhibiting decline of mitochondrial potential.
  • 2. Evaluation of Effect of Scavenging Reactive Oxygen Species Produced by Neurotoxins
  • The same cells used in Test Example 4-1 were cultured under the same condition. The cultured cells were treated with 0.01, 0.1 or 1 μM coumestrol and then treated with 50 μM 6-OHDA 2 hours later to induce increase of reactive oxygen species (ROS) in the cells. After culturing the cells for 6 hours in an incubator, the quantity of ROS in the cells was measured using DCFH-DA and the decrease of the ROS was evaluated relative to the negative control group. The fluorescence intensity of DCF was measured with the Wallac VICTOR2 fluorometer (Wallac, Turku, Finland) at excitation wavelength of 485 nm and emission wavelength of 530 nm. ROS scavenging effect (%) relative to the negative control group was calculated from the measured fluorescence intensity. The result is given in Table 5.
  • TABLE 5
    ROS scavenging effect (%)
    Negative control 0
    (50 μM 6-OHDA)
    Coumestrol, 0.01 μM 73.0
    Coumestrol, 0.1 μM 86.7
    Coumestrol, 1 μM 93.5
  • As seen from Table 5, coumestrol has an excellent effect of scavenging ROS produced by neurotoxins.
  • Accordingly, the composition comprising coumestrol may prevent or improve degenerative neurological disorders by inhibiting the action of neurotoxins.
  • Formulation examples of the composition according to the present disclosure are described hereinafter. However, the scope of the present disclosure is not limited to the following examples.
  • FORMULATION EXAMPLE 1 Soft Capsule
  • Coumestrol (80 mg), vitamin E (9 mg), vitamin C (9 mg), palm oil (2 mg), hydrogenated vegetable oil (8 mg), yellow beeswax (4 mg) and lecithin (9 mg) are mixed and prepared into a soft capsule filling solution according to a commonly employed method. 400 mg of the solution is filled per capsule. Separately from this, a soft capsule sheet is prepared using gelatin 66 (wt %), glycerin (24 wt %) and sorbitol (10 wt %), which is filled with the filling solution to prepare a soft capsule containing 400 mg of the composition according to the present disclosure.
  • FORMULATION EXAMPLE 2 Tablet
  • Coumestrol (80 mg), vitamin E (9 mg), vitamin C (9 mg), galactooligosaccharide (200 mg), lactose (60 mg) and maltose (140 mg) are mixed and granulated using a fluidized bed dryer. After adding sugar ester (6 mg), the resulting composition (500 mg) is prepared into a tablet according to a commonly employed method.
  • FORMULATION EXAMPLE 3 Drink
  • Coumestrol (80 mg), vitamin E (9 mg), vitamin C (9 mg), glucose (10 g), citric acid (0.6 g) and oligosaccharide syrup (25 g) are mixed. After adding purified water (300 mL), 200 mL of the resulting mixture is filled in a bottle. Then, a drink is prepared by sterilizing at 130° C. for 4-5 seconds.
  • FORMULATION EXAMPLE 4 Granule
  • Coumestrol (80 mg), vitamin E (9 mg), vitamin C (9 mg), anhydrous crystalline glucose (250 mg) and starch (550 mg) are mixed, granulated using a fluidized bed granulator, and then filled in a pouch.
  • FORMULATION EXAMPLE 5 Injection
  • Coumestrol 20 mg
    Sterilized distilled water for injection adequate
    pH adjuster adequate
  • An injection is prepared using the above ingredients per ampule (2 mL) according to a commonly employed method.
  • Those skilled in the art will appreciate that the present disclosure may be changed and modified variously within the scope of the present disclosure.

Claims (11)

1-6. (canceled)
7. A method for detoxifying toxic substances comprising administering an effective amount of coumestrol or a bean extract comprising coumestrol to a subject in such need to detoxify toxic substances.
8. The method of claim 7, wherein the coumestrol or bean extract comprising coumestrol detoxifies nicotine.
9. The method of claim 7, wherein the coumestrol or bean extract comprising coumestrol prevents or improves vascular diseases caused by toxic substances.
10. The method of claim 9, wherein the vascular disease comprises one or more of blood circulation disorder, hypertension and arteriosclerosis.
11-15. (canceled)
16. The method of claim 7, comprising administering coumestrol in a dose greater than about 50 mg/kg/day.
17. The method of claim 16, wherein the dose is up to about 5000 mg/kg/day.
18. The method of claim 17, wherein the dose is up to about 500 mg/kg/day.
19. The method of claim 7, comprising administering a bean extract wherein coumestrol is present in the bean extract in an amount of about 0.01 to about 50 percent by weight.
20. The method of claim 19, comprising administering a bean extract wherein coumestrol is present in the bean extract in an amount of about 0.1 to about 30 percent by weight.
US14/200,070 2010-03-31 2014-03-07 Composition comprising coumestrol or a bean extract containing coumestrol Abandoned US20140187621A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/200,070 US20140187621A1 (en) 2010-03-31 2014-03-07 Composition comprising coumestrol or a bean extract containing coumestrol

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2010-0029220 2010-03-31
KR20100029220 2010-03-31
PCT/KR2011/002233 WO2011122879A2 (en) 2010-03-31 2011-03-31 Composition comprising coumestrol or a bean extract containing coumestrol
US201213637966A 2012-09-27 2012-09-27
US14/200,070 US20140187621A1 (en) 2010-03-31 2014-03-07 Composition comprising coumestrol or a bean extract containing coumestrol

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2011/002233 Division WO2011122879A2 (en) 2010-03-31 2011-03-31 Composition comprising coumestrol or a bean extract containing coumestrol
US13/637,966 Division US20130028921A1 (en) 2010-03-31 2011-03-31 Composition comprising coumestrol or a bean extract containing coumestrol

Publications (1)

Publication Number Publication Date
US20140187621A1 true US20140187621A1 (en) 2014-07-03

Family

ID=44712773

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/637,966 Abandoned US20130028921A1 (en) 2010-03-31 2011-03-31 Composition comprising coumestrol or a bean extract containing coumestrol
US14/200,079 Active 2031-04-25 US9655878B2 (en) 2010-03-31 2014-03-07 Composition comprising coumestrol or a bean extract containing coumestrol
US14/200,064 Abandoned US20140187620A1 (en) 2010-03-31 2014-03-07 Composition comprising coumestrol or a bean extract containing coumestrol
US14/200,070 Abandoned US20140187621A1 (en) 2010-03-31 2014-03-07 Composition comprising coumestrol or a bean extract containing coumestrol

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US13/637,966 Abandoned US20130028921A1 (en) 2010-03-31 2011-03-31 Composition comprising coumestrol or a bean extract containing coumestrol
US14/200,079 Active 2031-04-25 US9655878B2 (en) 2010-03-31 2014-03-07 Composition comprising coumestrol or a bean extract containing coumestrol
US14/200,064 Abandoned US20140187620A1 (en) 2010-03-31 2014-03-07 Composition comprising coumestrol or a bean extract containing coumestrol

Country Status (4)

Country Link
US (4) US20130028921A1 (en)
KR (1) KR101384497B1 (en)
CN (3) CN104771395A (en)
WO (1) WO2011122879A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102200014B1 (en) 2013-05-06 2021-01-08 (주)아모레퍼시픽 Composition for preventing and treating climacteric symptoms comprising extract of bean containing coumestrol
WO2017074159A2 (en) * 2015-10-30 2017-05-04 (주)휴바이오 Coumestrol-containing germinated fermented soybean extract having hepatocyte protective effect and bone density increase effect and composition containing same
KR102249710B1 (en) * 2017-10-20 2021-05-10 (주)아모레퍼시픽 Composition for preventing hair loss and promoting hair growth comprising bean tissue cultured extract and mathod for preparing the same
JP6390805B1 (en) * 2018-01-09 2018-09-19 アルス株式会社 Reflective optical element and interferometer
KR20200040583A (en) * 2018-10-10 2020-04-20 (주)아모레퍼시픽 Composition for cortisone reductase inhibition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
US20120289714A1 (en) * 2010-01-29 2012-11-15 Amorepacific Corporation Method for preparing coumestrol and coumestrol prepared by same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE322903T1 (en) * 1999-07-09 2006-04-15 Sun Farm Corp DIETARY SUPPLEMENT FOR TREATING MALIGNANTS AND VIRUS INFECTIONS AND IMPROVING IMMUNE FUNCTION
US6334998B1 (en) * 1999-12-07 2002-01-01 Parker Hughes Institute Estrogens for treating ALS
DE60313754T2 (en) 2002-03-06 2008-01-24 The Medical Research and Education Trust, San Diego BOTANICAL EXTRACT WITH ANTICIPATIVE ACTIVITY INCLUDING ISOLIQUIRITIGENIN
CN1984648A (en) * 2003-03-06 2007-06-20 医学研究和教育联合企业 Botanical extract compositions and methods of use
US20050118290A1 (en) 2003-12-02 2005-06-02 University Of Singapore Compositions and method for treatment of steroid/nuclear receptor-mediated diseases
KR100706279B1 (en) * 2005-11-11 2007-04-12 (주)아모레퍼시픽 Medicine and food compositions for improvement of obesity
KR100701269B1 (en) * 2006-12-19 2007-03-29 (주)아모레퍼시픽 Medicine and Food Compositions for Improvement of Obesity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
US20120289714A1 (en) * 2010-01-29 2012-11-15 Amorepacific Corporation Method for preparing coumestrol and coumestrol prepared by same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Figuero et al., Oxidant/antioxidant interactions of nicotine, Coenzyme Q10, Pycnogenol and phytoestrogens in oral periosteal fibroblasts and MG63 osteoblasts, Steroids, 2006, Vol. 71, 1062-1072 *
Hwang et al., Soy and Alfalfa Phytoestrogen Extracts Become Potent Low-Density Lipoprotein Antioxidants in the Presence of Acerola Cherry Extract, Journal of Agricultural and Food Chemistry, 2001, Vol. 49, pp. 308-314 *
Thompson et al., Dietary Phytoestrogens, Including Isoflavones, Lignans, and Coumestrol, in Nonvitamin, Nonmineral Supplements Commonly Consumed byWomen in Canada, Nutrition and Cancer, 2007, Vol. 59, pp. 176-184 *

Also Published As

Publication number Publication date
CN104771395A (en) 2015-07-15
US20140187622A1 (en) 2014-07-03
US9655878B2 (en) 2017-05-23
CN102905715B (en) 2015-10-14
WO2011122879A3 (en) 2012-05-03
CN102905715A (en) 2013-01-30
WO2011122879A2 (en) 2011-10-06
US20140187620A1 (en) 2014-07-03
KR20110110054A (en) 2011-10-06
KR101384497B1 (en) 2014-04-10
CN103961397A (en) 2014-08-06
US20130028921A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
US9655878B2 (en) Composition comprising coumestrol or a bean extract containing coumestrol
US20210401916A1 (en) Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract
KR101800632B1 (en) Pharmaceutical composition, food composition or food additives for prevention, improvement or treatment of muscle loss, weakening, and atrophy comprising Enterococcus faecalis, it culture broth or heat killed Enterococcus faecalis as an active ingredient
KR101997060B1 (en) Composition for prevention or treatment of muscular disorder, or improvement of muscular functions comprising fermented deer antler
CN1278171A (en) Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, ihibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent
US8168237B2 (en) Medicinal herbal extract having anti-obesity effect
US11771726B2 (en) Composition, containing Quisqualis indica extract, for preventing or treating prostatic hyperplasia
KR20140147948A (en) Manufacturing Method for Allomyrina dichotoma extract having anti-Obesity effect and Anti-Obesity Composition Containing the same
KR101651908B1 (en) Composition for Prevention or Treatment diabetes comprising Tenebrio molitor larva or extract suspension of Tenebrio molitor larva
KR20170005632A (en) A composition comprising extract of Elaeagnus multiflora Thunb. for preventing or treating obesity or hyperlipidemia
CN1124133C (en) Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent
RU2668135C1 (en) Pharmaceutical composition for the treatment and prevention of degenerative neurological disorders which comprises, as an active ingredient, a mixed root extract of the tree peony root, the root of dahuric angelica and the root of thorowax or its fraction
KR101559483B1 (en) Neuroprotective composition comprising extracts or fractions of seaweed as an active ingredient
KR102292696B1 (en) Locusta Migratoria ethanol extract for inhibiting osteoclast differentiation and uses therof
KR102249795B1 (en) Composition for Improving Obesity or Exercise Performance comprising Extract from Inula japonica
CN104605344A (en) Health food for enhancing immunity and preparation method of health food
KR102517662B1 (en) Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising chaga
US10961176B2 (en) Compound hexadecaphlorethol isolated from Ishige okamurae and use thereof
KR20180034874A (en) Composition for Preventing or Treating Muscle Diseases Comprising Catechins Green Tea Extracts
KR20190006286A (en) Composition for treating or preventing inflammatory disease or obesity comprising an extract of schisandra chinesis
KR20220084817A (en) Anti-obese composition comprising water extract of Gymnaster koraiensis
KR20240013823A (en) Composition for improvement, prevention or treatment of muscular disorders, or improvement of muscular functions comprising tilianin
KR101413584B1 (en) A composition for preventing and treating bone diseases containing desmodii herba extracts as a active ingredient
KR20210019051A (en) A pharmaceutical composition comprising extract of Morus alba leaves treated with Pectinex for preventing or treating obesity
KR20080068982A (en) Inhibition activity of paecilomyces tenuipis in differentiation of adipocytes

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION